Quest Pharmatech Inc logo

QPT - Quest Pharmatech Inc News Story

C$0.16 0.0  0.0%

Last Trade - 10/08/20

Sector
Healthcare
Size
Micro Cap
Market Cap £15.4m
Enterprise Value £15.3m
Revenue £n/a
Position in Universe 1182nd / 2675

BRIEF-OncoQuest Signs Deal To Sell Drug Portfolio To Dual Industrial For $300 Mln

Wed 22nd April, 2020 5:55pm
April 22 (Reuters) - Quest Pharmatech Inc  QPT.V :
    * ONCOQUEST SIGNS A DEFINITIVE AGREEMENT TO SELL DRUG
PORTFOLIO TO
DUAL INDUSTRIAL FOR U.S. $300 MILLION AND COMMITMENT TO FUND THE
OREGOVOMAB PHASE 3 CLINICAL TRIAL IN FRONTLINE OVARIAN CANCER
    * QUEST PHARMATECH INC - DUAL WILL BE RESPONSIBLE FOR ALL
CLINICAL
AND NON-CLINICAL DEVELOPMENT EXPENSES FOR ONCOQUEST'S TECHNOLOGY
    * QUEST PHARMATECH INC - DUAL WILL SECURE $75 MILLION FOR
DEVELOPMENT WHICH IS EXPECTED NO LATER THAN JUNE 30, 2020 AND
WILL TRIGGER FIRST CLOSING
    * QUEST PHARMATECH -  ONCOQUEST-DUAL DEAL IS IN EXCHANGE FOR
U.S.$300 MILLION IN A COMBINATION OF DUAL COMMON STOCK AND DUAL
PERPETUAL CONVERTIBLE BONDS
    * QUEST PHARMATECH INC - AT EXECUTION DATE, ONCOQUEST SHALL
RECEIVE U.S. $125 MILLION IN A PERPETUAL CONVERTIBLE BOND
    * QUEST PHARMATECH - DUAL COMMITTED TO RETURNING 2.5 MILLION
ONCOQUEST SHARES; AS A RESULT, QUEST'S OWNERSHIP INTEREST IN
ONCOQUEST WILL RISE TO OVER 40%
    * QUEST PHARMATECH INC - ONCOQUEST WILL HAVE RIGHT TO
NOMINATE
FOUR BOARD MEMBERS TO AN EIGHT-PERSON DUAL BOARD

Source text for Eikon:  ID:nCNWpMmZFa 
Further company coverage:  QPT.V 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.